Welcome to our dedicated page for BioAge Labs news (Ticker: BIOA), a resource for investors and traders seeking the latest updates and insights on BioAge Labs stock.
BioAge Labs, Inc. (NASDAQ: BIOA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of therapies for metabolic diseases by targeting the biology of human aging. Company announcements highlight progress in its lead NLRP3 inhibitor program, preclinical obesity programs, and collaborations with larger pharmaceutical partners.
A key focus of recent news is BGE-102, a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor. BioAge has reported interim data from an ongoing Phase 1 single and multiple ascending dose trial, including information on safety, pharmacokinetics, and pharmacodynamic effects on inflammatory biomarkers such as IL-1β, hsCRP, IL-6, and fibrinogen in healthy volunteers and obese participants with elevated inflammation.
News updates also cover BioAge’s broader pipeline and strategy. The company issues releases on the advancement of long-acting injectable and oral small-molecule APJ agonists for obesity, including a nanobody APJ agonist under an exclusive option agreement and a portfolio of orally active APJ agonists. In addition, BioAge communicates developments in its discovery platform based on human longevity data and its multi-year collaborations with Novartis and Lilly ExploR&D on metabolic aging targets.
Investors following BIOA news can expect coverage of clinical milestones for BGE-102, preclinical and regulatory progress for APJ agonist programs, financial results, and participation in healthcare and biotechnology conferences. This page aggregates those updates so readers can review BioAge’s clinical data disclosures, partnership announcements, and strategic commentary in one place.
BioArctic (Nasdaq: B) published its Annual Report 2025, with the Sustainability Report and Corporate Governance Report integrated into the document. The company highlights a breakthrough Alzheimer’s drug now on the global market, several licence agreements, a broad pipeline and record-high profits in 2025.
The report aligns sustainability reporting with the European CSRD and ESRS frameworks and is available for download from the company's investor website.
BioAge (Nasdaq: BIOA) reported Phase 1 data for oral NLRP3 inhibitor BGE-102, showing rapid, large reductions in inflammatory biomarkers. In participants with obesity and elevated hsCRP, 60 mg QD (21 days) and 120 mg QD (14 days) produced median hsCRP reductions of ~85% and ~83–86%, respectively.
BGE-102 was well tolerated with no serious adverse events. BioAge plans a Phase 2 cardiovascular risk trial in H1 2026 with data expected H2 2026, and a Phase 1b/2a DME trial beginning mid-2026 with results anticipated mid-2027.
BioAge Labs (NASDAQ: BIOA) will present at the 25th Annual Needham Virtual Healthcare Conference April 13–16, 2026. CEO Kristen Fortney will take part in a fireside chat on April 16 from 3:00–3:30 PM EDT.
One-on-one meetings will include CFO Dov Goldstein and CSO BJ Sullivan. A live webcast is available by registration and replays will be archived for 30 days in the investor section of the company's website.
BioArctic (Nasdaq: B) announces the Nomination Committee's proposals for the Annual General Meeting on May 28, 2026. The committee proposes an eight-member board, re-electing Eugen Steiner as chair and six existing members, and adding Philip Scheltens and Linda Nilsson as new board members.
Pär Gellerfors has declined re-election; Linda Nilsson is proposed to represent the Gellerfors family's holding company. The Nomination Committee members represent ~57% of shares and ~83% of votes.
BioAge (NASDAQ: BIOA) reported full-year 2025 results and Q4 updates on March 24, 2026. Key clinical highlights include positive interim Phase 1 data for oral NLRP3 inhibitor BGE-102 with an 86% median hsCRP reduction at 120 mg and planned Phase 2a initiation in 1H 2026. The company completed an upsized follow-on offering raising $132.3 million and held $285.1 million in cash and marketable securities as of December 31, 2025, estimating funding through 2029.
BioArctic (NASDAQ: B) reported new data presented at AD/PD 2026 on long-term, real-world IV lecanemab treatment persistence and additional company presentations. Real-world claims analysis showed 78.4% persistence at 18 months, 71.7% at 20 months and 67.3% at 24 months. BioArctic also presented data on lecanemab binding to soluble Aβ protofibrils and a poster on exidavnemab trial screening using alpha-synuclein SAA. The release notes investigational status and no guarantee of regulatory approval.
BioArctic (Nasdaq Stockholm: B) issued 78,000 Class B shares in February 2026 under the 2019/2028 stock option program. As of February 27, 2026 the company had 88,719,485 shares: 74,319,489 listed Class B and 14,399,996 unlisted Class A. A shares carry ten votes; B shares carry one vote, giving a total of 218,319,449 votes.
Contact details for investor relations are provided for further inquiries.
BioAge Labs (NASDAQ: BIOA) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026. CEO Kristen Fortney will join a fireside chat on February 26 from 10:40 AM to 11:05 AM ET; management will hold one-on-one meetings.
Live webcast registration is available and replays will be archived on the company's investor website for 30 days.
BioArctic (NASDAQ Stockholm: B) will publish its fourth quarter report for October–December 2025 on 18 February 2026 at 08:00 a.m. CET. A presentation with CEO Gunilla Osswald and CFO Anders Martin-Löf will follow at 09:30 a.m. CET, including a Q&A, webcast and teleconference options.
Registration links, dial-in information, and archived webcast access are provided on the company's investor site. Contact details for investor relations are listed for follow-up.
BioArctic (NASDAQ: B) reports that Leqembi global sales were JPY 20.7 billion in Q4 2025, generating a royalty to BioArctic of SEK 127 million. This royalty rose ~31% versus Q4 2024; at constant exchange rates the SEK increase would be ~50%, reflecting currency effects.
Eisai will publish its Q3 FY2025 results on February 9, 2026 and BioArctic will publish its FY2025 report on February 18, 2026 at 08:00 CET.